Glaxosmithkline | GSK - Equity Capital And Reserves



Glaxosmithkline reported GBP14.35B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
AbbVie USD 1.46B 1.86B Mar/2025
Amgen USD 7.43B 1.22B Jun/2025
AstraZeneca USD 44.72B 3.68B Jun/2025
Aurora Cannabis CAD 588.68M 15.76M Jun/2025
Bausch Health Companies USD 147M 1.33B Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Canopy Growth CAD 488.98M 102.49M Jun/2025
Corcept Therapeutics USD 635.79M 47.49M Jun/2025
Drreddys Laboratories INR 353.76B 36.03B Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
GlaxoSmithKline GBP 14.35B 197M Jun/2025
Glaxosmithkline GBP 14.35B 683M Jun/2025
J&J USD 78.11B 6.62B Mar/2025
Merck USD 49.06B 725M Jun/2025
Novartis USD 42.05B 3.6B Jun/2025
Pacira USD 757.77M 40.77M Jun/2025
Perrigo USD 4.47B 108.3M Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
Prestige Brands USD 1.86B 20.58M Jun/2025
Roche Holding CHF 36.16B 3.28B Dec/2024
Sanofi 70.28B 3.8B Jun/2025
Supernus Pharmaceuticals USD 1.06B 33.2M Jun/2025
Takeda JPY 6.87T 69.82B Jun/2025
Teva Pharmaceutical Industries USD 6.83B 572M Jun/2025
Zoetis USD 4.98B 322M Jun/2025